# Trial to Investigate the Safety and Efficacy of GWP42003-P Versus Placebo as Adjunctive Therapy in Participants With Schizophrenia Experiencing Inadequate Response to Ongoing Antipsychotic Treatment

> **NCT04421456** · PHASE2 · TERMINATED · sponsor: **Jazz Pharmaceuticals** · enrollment: 95 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** GWP42003-P
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04421456
- **Lead sponsor:** Jazz Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-08-18
- **Primary completion:** 2022-03-16
- **Final completion:** 2022-03-16
- **Target enrollment:** 95 (ACTUAL)
- **Why stopped:** This study was terminated based on a business decision by the Sponsor.
- **Last updated:** 2023-06-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04421456

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04421456, "Trial to Investigate the Safety and Efficacy of GWP42003-P Versus Placebo as Adjunctive Therapy in Participants With Schizophrenia Experiencing Inadequate Response to Ongoing Antipsychotic Treatment". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04421456. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*